U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07446101) titled 'A Study of Mirikizumab Solution (LY3074828) in Healthy Participants' on Feb. 26.
Brief Summary: The main purpose of this study is to assess the safety and tolerability of mirikizumab (LY3074828) solution formulation administered as a single injection compared with two injections under the skin in healthy participants. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 15 weeks.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Healthy
Intervention:
DRUG: Mirikizumab
Administered SC
Recruitment Status: NOT_YET_RECRUITING
Sponso...